The standard treatment of care for melanoma metastatic to the inguinal lymph node basin is lymphadenectomy. However, up to 50% of patients forgo the operation partly due to concerns about morbidity. Videoscopic inguinal lymphadenectomy (VIL) is a minimally invasive technique designed to minimize wound complications while achieving comparable oncological control.
Methods
We reviewed pertinent literature related to open inguinal lymphadenectomy and VIL specific to melanoma, offering personal experience where appropriate.
Results
Despite efforts to minimize the complications of open inguinal lymphadenectomy, approximately 50% of patients experience a wound-related complication. However, performing minimally invasive VIL has led to a significant decrease in length of hospital stay, a decrease in complications, and equivalent or superior lymph node retrieval in patients with metastatic melanoma to the inguinal basin.
Conclusions
VIL is an alternative to open inguinal lymphadenectomy for patients with melanoma and regional metastases.
References
1.
MarkovicS.N., EricksonL.A., RaoR.D.. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis.Mayo Clin Proc.2007; 82(3): 364–380.
2.
MortonD.L.. Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma.Clin Exp Metastasis.2012; 29(7): 699–706.
BilimoriaK.Y., BalchC.M., BentremD.J.. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States.Ann Surg Oncol.2008; 15(6): 1566–1576.
5.
Tobias-MachadoM., TavaresA., MolinaWRJr. Video endoscopic inguinal lymphadenectomy (VEIL): initial case report and comparison with open radical procedure.Arch Esp Urol.2006; 59(8): 849–852.
6.
DelmanK.A., KoobyD.A., OganK.. Feasibility of a novel approach to inguinal lymphadenectomy: minimally invasive groin dissection for melanoma.Ann Surg Oncol.2010; 17(3): 731–737.
7.
ShawJ.H., RumballE.M.. Complications and local recurrence following lymphadenectomy.Br J Surg.1990; 77(7): 760–764.
8.
CoitD.G., PetersM., BrennanM.F.. A prospective randomized trial of perioperative cefazolin treatment in axillary and groin dissection.Arch Surg.1991; 126(11): 1366–1371.
9.
BeitschP., BalchC.. Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection.Am J Surg.1992; 164(5): 462–466.
de VriesM., VonkemanW.G., van GinkelR.J.. Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma.Eur J Surg Oncol.2006; 32(7): 785–789.
13.
van AkkooiA.C., BouwhuisM.G., van GeelA.N.. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.Eur J Surg Oncol.2007; 33(1): 102–108.
14.
SabelM.S., GriffithK.A., AroraA.. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy.Surgery.2007; 141(6): 728–735.
15.
GuggenheimM.M., HugU., JungF.J.. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma.Ann Surg.2008; 247(4): 687–693.
16.
PoosH.P., KruijffS., BastiaannetE.. Therapeutic groin dissection for melanoma: risk factors for short term morbidity.Eur J Surg Oncol.2009; 35(8): 877–883.
17.
ChangS.B., AskewR.L., XingY.. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients.Ann Surg Oncol.2010; 17(10): 2764–2772.
18.
SarnaikA.A., PuleoC.A., ZagerJ.S.. Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma.Cancer Control.2009; 16(3): 240–247.
19.
BishoffJ.T., BaslerJ.W., TeichmanJ.M.. Endoscopic subcutaneous modified inguinal lymph node dissection (ESMIL) for squamous cell carcinoma of the penis.J Urol.2003; 169: 78.
JacobsL.K., BalchC.M., CoitD.G.. Inguinofemoral, iliac/obturator, and popliteal lymphadenectomy in patients with melanoma. In: BalchC.M., HoughtonA.N., SoberA.J., eds. Cutaneous Melanoma.5th ed.St Louis, MO: Quality Medical Publishing Inc;2009: 460.
23.
JohnsonD.E., AmesF.C.. Groin Dissection.Chicago, IL: Year Book Medical Publishers;1985.
24.
MasterV.A., JafriS.M., MosesK.A.. Minimally invasive inguinal lymphadenectomy via endoscopic groin dissection: comprehensive assessment of immediate and long-term complications.J Urol.2012; 188(4): 1176–1180.
25.
CanterD.J., DobbsR.W., JafriS.M.. Functional, oncologic, and technical outcomes after endoscopic groin dissection for penile carcinoma.Can J Urol.2012; 19(4): 6395–6400.
26.
AbbottA.M., GrotzT.E., RuethN.M.. Minimally invasive inguinal lymph node dissection (MILND) for melanoma: experience from two academic centers.Ann Surg Oncol.2013; 20(1): 340–345.
27.
Clinical Outcomes of Surgical Therapy Study Group.A comparison of laparoscopically assisted and open colectomy for colon cancer.N Engl J Med.2004; 350(20): 2050–2059.
28.
PasqualiS., SpillaneA.J., de WiltJ.H.. Surgeons’ opinions on lymphadenectomy in melanoma patients with positive sentinel nodes: a worldwide web-based survey.Ann Surg Oncol.2012; 19(13): 4322–4329.
29.
SondakV.K., SarnaikA.A.. Minimizing morbidity while preserving outcome after inguinal lymphadenectomy: navigating between scylla and charybdis.Ann Surg Oncol.2011; 18(4): 909–911.
30.
NathansohnN., SchachterJ., GutmanH.. Patterns of recurrence in patients with melanoma after radical lymph node dissection.Arch Surg.2005; 140(12): 1172–1177.
31.
SpillaneA.J., TuckerM., PasqualiS.. A pilot study reporting outcomes for melanoma patients of a minimal access ilioinguinal dissection technique based on two incisions.Ann Surg Oncol.2011; 18(4): 970–976.
